Nucleoside Analog-Treated Patients’ Clinical and Laboratory Characteristics and Telomerase Activity
| Patients . | Therapy . | Time (mo after treatment) . | CD4 (/μL) . | Viral Load (log copies RNA per mL) . | Telomerase Activity (%) . |
|---|---|---|---|---|---|
| 1 | AZT | −32 | 480 | 3.0 | 0.001 |
| 1 | 26 | 160 | 5.0 | 0 | |
| 2 | AZT | −36 | 180 | 4.1 | 0.01 |
| 2 | 33 | 120 | 3.9 | 0.001 | |
| 3 | AZT/DDC | −31 | 670 | 3.2 | 0.001 |
| 3 | 28 | 410 | 4.1 | 0.001 | |
| 4 | AZT/DDC | −38 | 290 | 4.6 | 0.001 |
| 4 | 28 | 60 | 4.0 | 0 | |
| 5 | AZT/DDC | −25 | 650 | ND | 0.001 |
| 5 | 14 | 140 | ND | 0.001 | |
| 6 | AZT/DDI | −29 | 270 | 3.6 | 0.001 |
| 6 | 34 | 280 | 3.0 | 0 | |
| 7 | AZT/DDI | −7 | 330 | ND | 0.01 |
| 7 | 24 | 90 | ND | 0.001 | |
| 8 | AZT/DDC/DDI | −24 | 390 | 4.4 | 0 |
| 8 | 43 | 20 | 4.3 | 0 |
| Patients . | Therapy . | Time (mo after treatment) . | CD4 (/μL) . | Viral Load (log copies RNA per mL) . | Telomerase Activity (%) . |
|---|---|---|---|---|---|
| 1 | AZT | −32 | 480 | 3.0 | 0.001 |
| 1 | 26 | 160 | 5.0 | 0 | |
| 2 | AZT | −36 | 180 | 4.1 | 0.01 |
| 2 | 33 | 120 | 3.9 | 0.001 | |
| 3 | AZT/DDC | −31 | 670 | 3.2 | 0.001 |
| 3 | 28 | 410 | 4.1 | 0.001 | |
| 4 | AZT/DDC | −38 | 290 | 4.6 | 0.001 |
| 4 | 28 | 60 | 4.0 | 0 | |
| 5 | AZT/DDC | −25 | 650 | ND | 0.001 |
| 5 | 14 | 140 | ND | 0.001 | |
| 6 | AZT/DDI | −29 | 270 | 3.6 | 0.001 |
| 6 | 34 | 280 | 3.0 | 0 | |
| 7 | AZT/DDI | −7 | 330 | ND | 0.01 |
| 7 | 24 | 90 | ND | 0.001 | |
| 8 | AZT/DDC/DDI | −24 | 390 | 4.4 | 0 |
| 8 | 43 | 20 | 4.3 | 0 |
Abbreviation: ND, not detected.